Oct 03, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Xeris Biopharma Holdings, Inc. ( XERS ) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Oct 02, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Are Medical Stocks Lagging Amneal Pharmaceuticals ( AMRX ) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Sep 30, 2025 • Benzinga
NEUTRAL
Amneal to Report Third Quarter 2025 Results on October 30, 2025 - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) ( "Amneal" or the "Company" ) , a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to ...
Sep 26, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® ( omalizumab )
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for ...
Sep 04, 2025 • Benzinga
NEUTRAL
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - Amneal Pharmaceuticals ( NASDAQ:AMRX )
Another addition to Amneal's growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) today announced the U.S.
Sep 01, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Wall Street Analysts Think Amneal ( AMRX ) Could Surge 25.52%: Read This Before Placing a Bet
The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.